RBC Capital on Ascendis Pharma (ASND): 'Yorvipath Survey Suggests a Potential Upside To Peak Numbers'
Tweet Send to a Friend
RBC Capital analyst Luca Issi reiterated an Outperform rating and $210.00 price target on Ascendis Pharma (NASDAQ: ASND).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
